Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation.

× No keyword cloud information.

7 in total

1. Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation.

Authors: Weiyang He; Qiong Wang; Jennings Xu; Xiuling Xu; Mabel T Padilla; Guosheng Ren; Xin Gou; Yong Lin
Journal: Autophagy Date: 2012-10-10 Impact factor: 16.016

2. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.

Authors: Joshua E Allen; Varun V Prabhu; Mala Talekar; A Pieter J van den Heuvel; Bora Lim; David T Dicker; Jennifer L Fritz; Adam Beck; Wafik S El-Deiry
Journal: Cancer Res Date: 2015-02-13 Impact factor: 12.701

3. Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin.

Authors: Zhenni Sun; Lu Yue; Zan Shen; Yong Li; Aihua Sui; Tianjun Li; Qian Tang; Ruyong Yao; Yongning Sun
Journal: Oncol Lett Date: 2017-02-13 Impact factor: 2.967

4. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.

Authors: Joshua E Allen; Gabriel Krigsfeld; Luv Patel; Patrick A Mayes; David T Dicker; Gen Sheng Wu; Wafik S El-Deiry
Journal: Mol Cancer Date: 2015-05-01 Impact factor: 27.401

Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation.

1. Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation.

2. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.

3. Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin.

4. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.

5. DNAJB8 in small extracellular vesicles promotes Oxaliplatin resistance through TP53/MDR1 pathway in colon cancer.

Review 6. Genetic and biological hallmarks of colorectal cancer.

Review 7. Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL).